Medibank PvtASX:MPL +2.67%77 EBITDA Margin % is 10.92% as of Dec. 2025, which is 10% above its 10-year median of 9.92. GuruFocus rates ASX:MPL with a GF Score™ of 77/100 and a GF Value™ of A$4.38 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 369 Insurance companies, Medibank Pvt ranks worse than 73.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medibank Pvt's EBITDA for the
six
months ended in Dec. 2025 was A$501 Mil. Medibank Pvt's Revenue for the
six
months ended in Dec. 2025 was A$4,587 Mil. Therefore, Medibank Pvt's EBITDA margin for the quarter that ended in Dec. 2025 was 10.92%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medibank Pvt EBITDA Margin % Related Terms
Medibank Pvt EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medibank Pvt's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MPL vs FNF, AXS, FAF: EBITDA Margin % Comparison
For the Insurance - Specialty subindustry, Medibank Pvt's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medibank Pvt EBITDA Margin % vs Insurance Industry
For the Insurance industry and Financial Services sector, Medibank Pvt's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medibank Pvt's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medibank Pvt (ASX:MPL) has a EBITDA Margin % of 10.92% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medibank Pvt and its competitors. This is 10% above median its historical median of 9.92. Over the past decade, Medibank Pvt's EBITDA Margin % has ranged from 9.07 to 11.30. According to the industry distribution chart, Medibank Pvt ranks #273 out of 369 companies in the Insurance industry, placing it in the top 74%.
Is Medibank Pvt's EBITDA Margin % too high?
Medibank Pvt's current EBITDA Margin % of 10.92% is 10% above median its 10-year median of 9.92. Over the past 10 years, this metric has ranged from a low of 9.07 to a high of 11.30. The Insurance industry median EBITDA Margin % is 14.81. Medibank Pvt's value of 10.92% is 26.3% below this industry median. Based on the distribution chart, Medibank Pvt ranks #273 out of 369 companies in the Insurance industry, which is below the industry midpoint. Overall, Medibank Pvt has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medibank Pvt's EBITDA Margin % compare to FNF and AXS?
According to the Insurance industry distribution chart, Medibank Pvt ranks #273 out of 369 companies for EBITDA Margin %. This places Medibank Pvt in the lower half of its industry. The industry median EBITDA Margin % is 14.81. Medibank Pvt's value of 10.92% is 26.3% below this benchmark. Historically, Medibank Pvt's own EBITDA Margin % has ranged from 9.07 to 11.30 over the past decade. While the company's 10-year median is 9.92 vs. the industry median of 14.81, Medibank Pvt has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Insurance company?
The median EBITDA Margin % among Insurance companies is 14.81, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medibank Pvt's current EBITDA Margin % of 10.92% is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medibank Pvt and its competitors. For the Insurance industry, the median EBITDA Margin % is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medibank Pvt's current EBITDA Margin % is 10.92%, which is 10% above median its own 10-year median of 9.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medibank Pvt stock overvalued right now?
Based on GuruFocus' analysis, Medibank Pvt (ASX:MPL) is currently considered Modestly Overvalued. The stock's GF Value™ is A$4.38, compared to a current price of A$4.99 — trading 13.9% above its estimated fair value. The current EBITDA Margin % is 10.92%, which is 10% above median its 10-year median of 9.92 and 26.3% below the Insurance industry median of 14.81. Medibank Pvt's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medibank Pvt (ASX:MPL), the current EBITDA Margin % is 10.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medibank Pvt (ASX:MPL) Overvalued in 2026?
Based on GuruFocus' analysis, Medibank Pvt stock appears to be overvalued.
The current stock price of A$4.99 is trading 13.9% above its estimated GF Value™ of A$4.38.
GuruFocus considers Medibank Pvt to be Modestly Overvalued.
Key valuation signals for ASX:MPL:
EBITDA Margin %: 10.92% (10% above median its 10-year median of 9.92)
GF Value™: A$4.38 vs. price of A$4.99 (13.9% above fair value)
Industry Position: 26.3% below the Insurance median (#273 of 369)
No single metric tells the full story. See the ASX:MPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Previously owned by the Australian government, Medibank is the largest health insurer in Australia. Its two brands, Medibank Private and Ahm, cover around 5 million people. Medibank and Australia's fourth-largest health fund, NIB Holdings, are the only listed health insurers. In addition to private health insurance, the firm provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.
77GF Score
Get the complete analysis for ASX:MPL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MPL has been successfully added to your 
